Eos Energy Enterprises Inc vs GSK plc — how do they compare? Eos Energy Enterprises Inc trades at $4.19 (market cap $1.54B), while GSK plc trades at $50.39 (market cap $102.60B). The key difference: GSK plc is far larger — about 66.6× Eos Energy Enterprises Inc's market cap, and GSK plc pays a 3.57% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals.
| EOSE | GSK | |
|---|---|---|
Market Cap | $1.54B | $102.60B |
Sector | Energy | Health |
52-Week High | $19.19 | $61.18 |
52-Week Low | $3.14 | $38.22 |
Enterprise Value | $1.88B | $123.04B |
Dividend Yield | — | 3.57% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $4.38, up 8.15% on the day, amid mixed technical signals and persistent fundamental challenges. The company reported a Q2 2026 loss of $1.20 per share, missing estimates, but revenue growth is accelerating, with 2026 revenue projected at $214 million. Negative profit margins and cash burn remain significant concerns, though analyst sentiment shows a mixed but cautious outlook with a consensus price target of $7.75.
The stock presents a high-risk opportunity driven by revenue growth potential in energy storage, but investors face substantial risks from continued losses, dilution, and competitive pressures. Upside depends on execution improving margins and achieving profitability, while downside risks include further earnings misses and liquidity challenges.
GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.
Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.
Trailing returns across standard periods
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →